[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"human-papillomavirus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:human-papillomavirus":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,37,68,99,130],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":25,"lastUpdatePostDateStruct":26,"startDateStruct":29,"completionDateStruct":31,"leadSponsor":33,"locationsCount":36},"100549462","evaluation-of-a-novel-point-of-care-diagnostic-test-for-human-papillomavirus-hpv-100549462",false,"NCT06434337","Evaluation of a Novel Point-of-Care Diagnostic Test for Human Papillomavirus (HPV)","Inclusion Criteria:\n\n1. People with a cervix 21 years of age or older.\n2. Scheduled to undergo hrHPV testing at MD Anderson and The Harris Health System (LBJ Hospital) according to national and institutional guidelines at time of enrollment OR are anticipated to undergo a LEEP, ECC, or biopsy.\n3. Willing and able to provide informed consent.\n4. Able to perform protocol-required activities. Able to speak and read English or Spanish.\n\nExclusion Criteria\n\n1. Patient or provider decision not to perform HPV testing. This does not apply to patients that are undergoing either a LEEP, ECC or biopsy.\n2. Participant or provider decision not to collect a sample for this study.\n3. Participants that are pregnant.","FEMALE","21 Years",{"count":18,"type":19},600,"ESTIMATED","OBSERVATIONAL","To learn if new HPV tests can provide the same results as standard HPV tests. The findings from this study may aid in the development of new HPV tests that require less equipment and are more accessible.",[23],"Human Papillomavirus","RECRUITING","2026-05-14",{"date":27,"type":28},"2026-05-18","ACTUAL",{"date":30,"type":28},"2024-07-23",{"date":32,"type":19},"2028-03-31",{"name":34,"class":35},"M.D. Anderson Cancer Center","OTHER",1,{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":41,"acronym":4,"eligibilityCriteria":42,"healthyVolunteers":43,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":49,"conditions":50,"keywords":51,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":36},"100441268","natural-history-epidemiology-and-pathogenesis-of-severe-hpv-related-diseases-neptune-100441268","NCT05026138","Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune)","* INCLUSION CRITERIA:\n\nInclusion Criteria for All Participants\n\n1. Aged \\>=3 years (except for household contacts and sexual partners of participants with HPV-related diseases, who must be aged 18 years and older).\n2. Able to provide informed consent or, if younger than 18, be accompanied by a parent(s)\u002Flegal guardian(s) who is able to provide informed consent.\n3. Willing to allow genetic testing on their collected biological samples.\n\nAdditional Inclusion Criteria for Participants with HPV-related Diseases\n\nHas severe, disseminated, recurrent, and treatment-refractory HPV infection, defined as one or more of the following confirmed by medical record review or participant health history:\n\n1. In participants without known primary or acquired immunodeficiency:\n\n   1. Multiple skin warts (\\>=5) recurrent\\* or refractory to standard-of-care interventions (eg, topical imiquimod, acetylsalicylic acid, cryotherapy, cantharidin, podophyllotoxin, bleomycin, cauterization, cidofovir, fluorouracil).\n   2. Concomitant skin warts (irrespective to recurrence or treatment response) AND any historical or current clinical and\u002For histologic or cytologic evidence of mucosal HPV-related diseases (oral, nasal, laryngeal, vaginal, anal, penile, or cervical).\n   3. Mucosal condyloma or other HPV-related diseases that are recurrent\\* or refractory to standard-of-care interventions.\n   4. Historical evidence of mucosal condyloma or any HPV-related diseases occurring irrespective of response to standard-of-care interventions and involving more than one mucosal site.\n2. In participants with known primary or acquired immunological defect (including idiopathic CD4 lymphopenia, immunosuppressive treatment, or HIV\u002FAIDS):\n\n   a. Any skin OR mucosal HPV-related diseases\n3. In any participant:\n\n   1. Recurrent invasive skin or mucosal HPV-related squamous cell carcinoma (HPV-SCC).\n   2. Historical or current histologic evidence of invasive HPV-SCC of any mucosal site in subjects with family history of HPV-SCC in 1 or more family members.\n\n      * The lack of complete response to 2 or more interventions is defined as treatment-refractory disease in the protocol, while the reappearance of a skin or mucosal lesion after complete resolution is defined as recurrence.\n\nAdditional Inclusion Criteria for Controls\n\n1\\. Biological relative, household contact, or sexual partner of the index participant (with HPV-related diseases) who meets one of the following criteria:\n\n1. does not have any historical or current clinical and\u002For histologic or cytologic evidence of skin or mucosal HPV-related diseases, or\n2. has historical or current clinical and\u002For histologic or cytologic evidence of skin or mucosal HPV-related diseases but does not meet the criteria to be enrolled in this study as a participant with HPV-related disease.\n\nEXCLUSION CRITERIA:\n\nIndividuals meeting any of the following criteria will be excluded from study participation:\n\n1. Laboratory abnormalities contraindicating research evaluations and procedures in patients without previous history of cytopenias: neutropenia (absolute neutrophil count \\\u003C500 cells\u002FmicroL) or thrombocytopenia (platelets \\\u003C10,000\u002FmicroL). Medical record review may be used to for determining eligibility if the laboratory tests were collected \\\u003C= 90 days prior to the screening visit.\n2. Inability to reliably keep research appointments and\u002For adhere to research procedures.\n3. Any condition that, in the opinion of the investigator, contraindicates participation in this study.\n\nAdditional Exclusion Criteria for Controls\n\n1\\. Has HPV-related disease that may indicate enrollment as an affected participant rather than as a healthy biological relative, household contact, or sexual partner.\n\nCo-enrollment guidelines: Participants may be co-enrolled in other studies; however, study staff should be notified of co-enrollment.",true,"ALL","3 Years","100 Years",{"count":48,"type":19},850,"Background:\n\nMost symptoms of human papillomaviruses (HPV) infection, do not cause serious health problems, but some do. As HPV can cause uncontrolled growth of infected cells, some people can develop benign skin lesions, larger warts, genital lesions, tumors or cysts that do not respond to treatment. Researchers want to learn why.\n\nObjective:\n\nTo better understand why some people are more likely than others to get sick from HPV infection, and why medicine or surgery is not always effective.\n\nEligibility:\n\nPeople aged 3 years and older who have had multiple outbreaks of HPV-related warts and\u002For lesions that do not respond to treatment. Healthy relatives are also needed.\n\nDesign:\n\nParticipants will be screened with a medical history, physical exam, and blood tests.\n\nParticipants may have study visits as an outpatient or an inpatient (admitted overnight to the NIH hospital) and be followed over several years by our doctors and researchers at the NIH.\n\nParticipants may have a cervical and\u002For anal Pap test. They may give samples of semen, cervicovaginal secretions, urine, saliva, or stool. Small pieces of skin, the inside of the cheek, and\u002For the gums may be collected with a punch or scrape biopsy to understand how HPV affect the growth of cells.\n\nMucus and skin may be collected by rubbing the area with a cotton swab. Collection areas may include the inside the mouth, nostrils, skin, genitals, and\u002For in or around the anus.\n\nBiopsies may be collected. If participants need to have a biopsy as part of medical care, then we may ask if extra samples can be collected for research. Biopsies we may collect are bone marrow, lymph node, genitals, or in or around the anus.\n\nParticipants may have leukapheresis. Blood is taken from a needle placed in one arm. A machine separates out the white blood cells. The rest of the blood is returned through a needle in their other arm.\n\nSamples may be used for genetic tests and\u002For to make special cells called induced pluripotent stem cells.\n\nParticipants may have follow-up visits once a year for 10 years.\n\nBenefits:\n\nWe are not testing new HPV treatments in this study and you might not benefit from participating. However, we may learn new information about your condition that we will share with you and your doctor. We may make recommendations for your medical care based on current accepted treatment.\n\nWhat we learn from you and other participants in this study might help other people. We hope we can use this information to develop new treatments and therapies in the future....",[23],[52,53,54,55,56,57],"Mucosal Disease","Immunocompromised","Genetic Defects","Infection","Neoplasia","Natural History","2026-04-10",{"date":60,"type":28},"2026-04-13",{"date":62,"type":28},"2021-11-17",{"date":64,"type":19},"2047-03-31",{"name":66,"class":67},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":43,"sex":15,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":36},"100490961","phase-4-comparing-immune-response-of-2-vs-3-hpv-doses-27-45-years-old-100490961","NCT05672927","Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)","Comparison of the Immune Response After Administration of 2 vs. 3 Doses of the FDA-approved 9-Valent HPV Vaccine Among Women 27-45 Years of Age","Inclusion criteria:\n\n1. Females 27-45 years old.\n2. Ability to give informed consent.\n3. Has not received any prior doses of the HPV vaccine. This will be verified by the person and state registry (Immtrac), as well as the person's electronic medical record.\n4. Reliable telephone access for the duration of the project.\n5. Can read and speak in either English or Spanish.\n6. Identified source of funding for vaccine such as Medicaid, private health insurance, Texas Healthy Women program, etc.\n7. Reports consistent use of reliable birth control and plans to continue its use through study month 13.\n\nExclusion criteria:\n\n1. Currently pregnant or plans to become pregnant or donate eggs in the next 13 months. Any subjects with positive pregnancy tests at the initial visit will be disqualified from the study and advised to seek prenatal care.\n2. Has an immunodeficiency or autoimmune disease such as HIV infection, lymphoma, leukemia, lupus, rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition.\n3. Currently receiving treatment or medication that can suppress immune function including radiation therapy, chemotherapy, cyclosporin, leflunomide (Arava), TNF-α antagonists, monoclonal antibody therapies (including rituximab \\[Rituxan\\]), intravenous gamma globulin (IVIG), antilymphocyte sera, other therapy known to interfere with the immune response, or systemic corticosteroids (by mouth or intramuscular injection). Those using or have used steroids that are inhaled, placed in the eye, applied on the skin, or injected into the joint\u002Fsoft tissue will be considered eligible for the study.\n4. History of splenectomy\n5. Known allergies to any vaccine components, including aluminum, yeast or Benzonase.\n6. Febrile at ≥100°F in the 24 hours prior to vaccination. The patients may be rescheduled for a later date.\n7. History of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.\n8. History of \\>10 sexual partners in their lifetime at time of enrollment\n9. Plans to move out of the Galveston\u002FHouston area in the 13 months following study entry.","27 Years","45 Years",{"count":78,"type":19},618,"INTERVENTIONAL",[81],"PHASE4","The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.",[84,85,23],"Immunization","HPV Infection",[87,88,89],"HPV vaccination","Gardasil 9","Noninferiority trial","2025-10-02",{"date":92,"type":28},"2025-10-06",{"date":94,"type":28},"2023-01-18",{"date":96,"type":19},"2027-08",{"name":98,"class":35},"The University of Texas Medical Branch, Galveston",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":44,"minAge":16,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":79,"phases":110,"briefSummary":112,"conditions":113,"keywords":114,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":36},"100467306","provider-recommendation-and-hpv-vaccination-100467306","NCT05365048","Provider Recommendation and HPV Vaccination","Effectiveness and Mechanisms of Multilevel Implementation Strategies to Improve Provider Recommendation and Advance HPV Vaccination: a Cluster Randomized Trial","HPVV","Inclusion Criteria:\n\n* All KPSC pediatric clinics.\n* All providers (physicians, nurses, and medical assistants) and department administrators from the pediatric department.\n* Parents of HPV vaccine-eligible children (9-12 years old).\n\nExclusion Criteria:\n\n* Providers and administrators who do not work for the pediatric department\n* Parents of children older than 12 years and\u002For who did not have a clinic visit in the study period.","70 Years",{"count":109,"type":19},301201,[111],"NA","In the United State, there are millions of US teens who are not vaccinated against the human papillomavirus (HPV) putting them at risk of getting HPV-related cancers. Although there are clinical guidelines recommending the HPV vaccine and interventions encouraging parents to vaccinate their children to prevent HPV-related cancers, the vaccination rate for teens remains low according to a 2018 national survey. Survey data shows that HPV vaccine complete series coverage for teens aged 13-15 years was 50%, far below the 80% target of Healthy People 2020. Receiving a strong provider recommendation is the most powerful strategy for improving HPV vaccine rates. Yet, little is known about how to include provider recommendations and other important factors into an intervention to improve the HPV vaccination rates. Studies show there are provider, patient and system-level barriers in the initiation and completion of HPV vaccine series among 9-12 years old children. Barriers to the HPV vaccine also differ across demographic subgroups, communities, and clinics. Interventions that address only one component are not responsive to site barriers and as effective as one that addresses multiple components and site-specific barriers. This study uses a 3-arm cluster randomized controlled trial (RCT) to compare three implementation strategies to improve provider recommendations on the HPV vaccine. Two of the implementation strategies (local-tailored and prescribed strategy) utilize a multilevel approach. The three implementation strategies of interest are (1) a \"local-tailored\" implementation strategy, co-designed with local care teams to address local barriers and contexts (2) A \"prescribed\" strategy, most commonly used by health systems, that involves pre-specified interventions addressing pre-selected vaccination barriers and (3) usual standard of care where there are no research-led activities. We will use surveys, interviews, and electronic health records to evaluate the three implementation strategies and their impact on improving HPV vaccination rates. The study surveys and interviews will include pediatric providers, nurses, administrators, staff members, and parents of HPV vaccine-eligible children (9-12 years old). Successful implementation will be defined as improvement in HPV vaccination rates (primary outcome), strengthening provider recommendation (secondary outcome), and the cost-effectiveness of the implementation strategy.",[23],[23,115,116,117,118,119,120],"Vaccine","Local Tailoring","4 Pillars","Prescribed Strategy","Implementation Strategy","Provider Recommendation","2025-05-15",{"date":123,"type":28},"2025-05-20",{"date":125,"type":28},"2022-03-21",{"date":127,"type":19},"2026-06-30",{"name":129,"class":35},"Kaiser Permanente",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":15,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":79,"phases":141,"briefSummary":142,"conditions":143,"keywords":144,"overallStatus":24,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":36},"100431687","multi-site-hpv-screening-by-high-throughput-sequencing-in-patients-with-chronic-hpv-hr-infection-followed-by-gynecology-100431687","NCT04901351","Multi-site HPV Screening by High-throughput Sequencing in Patients With Chronic HPV-HR Infection Followed by Gynecology","Feasibility of a Multi-site Screening Strategy in HPV+ Patients at High Risk of Cancer, With Characterization of the HPV Subtypes Involved by High Throughput Sequencing Technique: DEP-HPV","DEP-HPV","Inclusion Criteria:\n\n-Chronic infected patients defined by: Patients with persistent HPV-HR cytological infection (high risk) (as early as 6 months post-treatment of a cervical or vaginal injury), or a recurrence of a high-grade squamous intraepithelial lesion (CIN2 or CIN3 or HSIL) or a recurrence of cancer in the cervix or vagina\n\n* Patients who have given their written consent to participate in the study.\n* Person affiliated or beneficiary of a social security scheme.\n\nExclusion Criteria:\n\nPatient with an infection or a persistent lesion after treatment or not, linked only to low-risk HPV.","18 Years",{"count":140,"type":19},30,[111],"The main risk of developing cervical cancer is the persistence of an High risk human papillomavirus (HPV-HR) infection, the mechanisms of which are still not understood. These chronically infected patients could develop multi-site lesions. The main objective is to assess the feasibility of setting up a personalized screening in patients at high risk of cervical cancer (chronically infected with HPV), by evaluating documenting the acceptability of these patients to be sampled from the ENT sphere and anal spheres for HPV analysis with next-generation sequencing.",[23],[145,146,147,148],"Cervical cancer","Anal cancer;","ENT cancer","Next generation sequencing","2024-07-18",{"date":151,"type":28},"2024-07-19",{"date":153,"type":28},"2022-06-21",{"date":155,"type":19},"2025-12",{"name":157,"class":35},"University Hospital, Toulouse"]